Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Avance Pharma
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.
Additional Chinese coronavirus vaccine makers are now building up capacity, with Beijing-based AIM Vaccine preparing for a 400 million dose per year production capability for mRNA vaccines, while Chengdu-based Clover is to supply up to 414 million doses of its vaccines to GAVI.
Paths to commercialization are uncertain in nutrigenomics, an emerging science which seeks to identify gene-food interactions that differ among subpopulations and between individuals and to personalize diets to prevent disease.
These days, consumers reach for calcium-fortified orange juice to keep bones healthy, whole-grain Cheerios that reduce the risk of heart disease and cancer, and bags of walnuts that advertise Omega 3, for heart health. The founders of WellGen believe the time is right to push the frontier of food science into medicine. With a patent from Rutgers University, WellGen will screen food substances against genes implicated in diseases.